Benefit assessment at Winicker Norimed
The benefit assessment of new medicinal products within the context of the AMNOG, the German Pharmaceuticals Market Reorganisation Act, has far-reaching economic consequences for the respective company. This is why we provide our clients consulting based on the latest science and data, not only in terms of medical and scientific issues, but in particular on how to demonstrate a medicinal product’s benefit after authorization in compliance with applicable legal requirements.
Our highly-qualified employees, most of whom have years of experience in the pharmaceutical industry, will be happy to advise you on the complex topics and various issues that arise over the lifecycle of a medicinal product – a major success factor for marketing your product.
in benefit assessment
for benefit assessment
+49 (0) 89 / 2306 968 70